Subscribe

Glossary

Biologics

Drugs made from living cells that block one exact part of the immune system. Most are injections or drips rather than tablets, and they're used when the older tablets aren't enough.

These drugs aim at one target instead of damping everything down. That's the whole idea behind them. It explains both what they do well and what they cost you in the process.

Quick answerBiologics are drugs grown in living cells, where each one blocks a single signal in the immune system, and most are injected. They get used when tablets aren't enough. One review pooled 21 trials and 8361 people with early rheumatoid arthritis, where several biologics beat methotrexate alone on remission.
Beating methotrexate in a trial is one thing, and being the right next step is another. One trial put three older tablets against methotrexate plus a biologic, where disease control came out equal and people stayed on the tablets longer, at 78 percent against 63 percent at a year. The authors point at cost. So these drugs work, and they aren't the automatic next move, because your team weighs things a trial can't capture and cost is only one of them.

What a biologic is

A biologic is a drug grown in living cells rather than mixed from chemicals, and each one blocks a single signal that the immune system uses to keep inflammation going. That's why they're named for what they block rather than for what they treat. A tumor necrosis factor blocker blocks tumor necrosis factor, and an interleukin 6 blocker blocks interleukin 6.

One consequence of naming a drug by its target is that a drug can turn up in several different diseases. Most of them are given by injection under the skin, or by a drip into a vein, and that isn't for effect or ceremony. A protein that size wouldn't survive being swallowed.

How they differ from the tablets

The older tablets damp the immune system down broadly, and methotrexate is the one most people meet first. A biologic aims at one part of it and leaves the rest alone, which is the argument for them. It's also the reason their risks aren't one risk across the whole class.

Broad damping leaves a broad weakness, while blocking one signal well leaves a specific hole, and which hole depends on which drug. So safety can't be discussed for the group as a whole, however convenient that would be. The evidence here treats them as a group where the trials did, and splits them where the trials did.

Staying on the drug

How long people stay on a drug is measured separately from how well it works, and the two don't always agree. It's worth knowing both figures before a drug gets chosen. One study tracked 7089 people in ordinary Australian practice.

The median time on upadacitinib was 26.6 months, from 24.9 to 30.8, against 13.3 months on tumor necrosis factor blockers, from 11.5 to 14.5, at a P under 0.001. Against other drugs in its own group it was 28.8 months against 17.2. Read that with care, because patients were not assigned to anything and a newer drug reaches patients and prescribers already inclined to stick with it.

No statistical matching fixes what was never written down, and the study's own record here notes it. One finding from that study comes out cleaner than the rest. Taking upadacitinib alone gave much the same staying power as taking it with a tablet, at 27.8 months against 30.4 months, at a P value of 0.84.

Common misconceptions.

Myth. A biologic is just a stronger kind of tablet.

Reality. It works a different way entirely. A tablet like methotrexate damps the whole immune system down, while a biologic blocks one signal and leaves the rest alone, which is why each one is named for what it blocks. It also explains the main risk, because damping everything leaves a broad weak spot while blocking one signal leaves a small and precise one.

Myth. If the tablets aren't working, a biologic is the next step.

Reality. That's one option, and the trials don't make it the only one. One trial took people whose methotrexate wasn't enough and gave them either three older tablets together or methotrexate plus a biologic, where disease activity came out level and people stayed on the three tablets longer, at 78 percent against 63 percent at a year. The authors also point at the cost difference.

Myth. They all work about alike.

Reality. The rankings say otherwise, with one caution attached. One review pooled 21 trials and 8361 people, where adalimumab with methotrexate came first for remission, at an odds ratio of 2.90 from 1.94 to 4.33. Tocilizumab with methotrexate led on the strictest measure instead, at 4.41 from 2.29 to 8.49. Those same authors say the best plan stays unsettled, because too few trials qualified.

Myth. I have to take methotrexate alongside it.

Reality. Often yes, and not always. One registry watched people already in remission on etanercept plus a tablet, some of whom then dropped the tablet, and at two years 75 percent of those were still in remission or low activity against 86 percent on the pair. The adjusted P value was 0.057, which doesn't show the two are equal and doesn't show the tablet is essential either.

Myth. Any tablet will do as the partner drug.

Reality. It depends which biologic you're on. One review found that alongside rituximab, leflunomide beat methotrexate for a good response, at a risk ratio of 1.38 from 1.13 to 1.68. Alongside abatacept the two were alike, and alongside a tumor necrosis factor blocker methotrexate did better, at a risk ratio of 0.93 from 0.87 to 1.0. So the pairing is a real decision.

Related terms.

References.

  1. Xu H; Li C; Ding R et al. Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025;10:5. 10.1186/s41927-025-00603-xSystematic review and network meta-analysis of randomised controlled trials to February 2025
  2. Breedveld FC; Weisman MH; Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. 10.1002/art.21519PREMIER: two-year
  3. Youssef P; Ciciriello S; Tahir T et al. Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatol Ther. 2025;12:173-202. 10.1007/s40744-024-00736-4Retrospective non-interventional study of electronic medical records from the Australian OPAL dataset
  4. Peper SM; Lew R; Mikuls T et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. Arthritis Care Res (Hoboken). 2017;69:1467-1472. 10.1002/acr.23255Open-label extension of a 48-week double-blinded noninferiority randomised trial
  5. Pappas DA; Shan Y; Lesperance T et al. Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatol. 2020;2:588-594. 10.1002/acr2.11168Analysis of the Corrona rheumatoid arthritis registry
  6. Decarriere G; Barnetche T; Combe B et al. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021;73:873-884. 10.1002/acr.24195Systematic literature review with meta-analysis comparing methotrexate against other conventional synthetic disease-modifying drugs when combined with advanced therapies in rheumatoid arthritis
  7. Marsal Barril S; Martin-Martinez MA; Blanco-Garcia FJ et al. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting. Reumatol Clin (Engl Ed). 2022;18:567-573. 10.1016/j.reumae.2021.12.004Prospective multicenter non-controlled study over 32 weeks
  8. RUDWALEIT M; GOOCH K; MICHEL B et al. Adalimumab Improves Sleep and Sleep Quality in Patients with Active Ankylosing Spondylitis. The Journal of Rheumatology. 2010;38:79-86. 10.3899/jrheum.100213OPEN-LABEL
  9. O'Neill SM; Leahy J; Harte M et al. The efficacy and safety of Janus kinase inhibitors in adults with rheumatoid arthritis: a systematic review and cumulative meta-analysis. Semin Arthritis Rheum. 2025;75:152885. 10.1016/j.semarthrit.2025.152885Systematic review and cumulative meta-analysis of randomised controlled trials in adults with rheumatoid arthritis treated with a JAK inhibitor against placebo or active treatment
  10. Choy E; Freemantle N; Proudfoot C et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5:e000798. 10.1136/rmdopen-2018-000798Systematic literature review and network meta-analyses of 24-week efficacy and safety outcomes
  11. van Vollenhoven R; Strand V; Takeuchi T et al. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. Arthritis Res Ther. 2024;26:143. 10.1186/s13075-024-03358-xLong-term extension of the SELECT-EARLY phase 3 randomised controlled trial

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.